An experimental medicine from Protagonist Therapeutics stabilized red blood cells and improved symptoms in patients with a ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

A man who donated his stem cells in a bid to save the life of a critically ill patient has said his work at an NHS hospital ...

Protagonist Therapeutics (NASDAQ:PTGX) and Takeda (NYSE:TAK) said on Monday that its late-stage study of rusfertide for the ...

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the ...

Trial at the Johns Hopkins Kimmel Cancer Center and other centers finds reduced-intensity haploidentical bone marrow ...

Takeda’s $300 million bet on Protagonist Therapeutics’ hematology asset a year ago appears to have paid off as the drug ...

Protagonist Therapeutics notches a milestone in its pact with Takeda for rusfertide. New data show that many patients with a ...

In the first instalment of a series to mark the 10th anniversary of the Future Science Prize, Holly Chik and Shen Xinmei look ...

ROCKFORD, Ill. (WIFR) - The Rock River Valley Blood Center needs the community’s help to save lives. The center says it is in ...